NASDAQ: NLTXNeoleukin Therapeutics Inc Stock
$0.82+0.01 (+1.23%)
Updated May 26, 2023
NLTX Price
$0.82
Fair Value Price
$1.50
Market Cap
$35.12M
52 Week Low
$0.38
52 Week High
$1.34
P/E
-0.8x
P/B
0.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$56.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$45M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NLTX Overview
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NLTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NLTX ($0.82) is undervalued by 45.19% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NLTX ($0.82) is significantly undervalued by 45.19% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NLTX due diligence checks available for Premium users.
Be the first to know about important NLTX news, forecast changes, insider trades & much more!
NLTX News
Valuation
NLTX fair value
Fair Value of NLTX stock based on Discounted Cash Flow (DCF)
Price
$0.82
Fair Value
$1.50
Undervalued by
45.19%
NLTX ($0.82) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NLTX ($0.82) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NLTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.8x
Industry
14.7x
Market
54.23x
NLTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
1.74x
NLTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NLTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.2M
Profit Margin
0%
NLTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$98.5M
Liabilities
$17.1M
Debt to equity
0.21
NLTX's short-term assets ($85.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NLTX's short-term assets ($85.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NLTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NLTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.0M
Investing
$10.7M
Financing
-$66.0k
NLTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NLTX vs Pharmaceutical Stocks
Neoleukin Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.